Emami Ltd Q1 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/f816ua16p3o7hwk0d6bxxj71.pdf

Key Takeaways


Category Headwinds & Offsetting Growth

Mohan Goenka: "But it is not possible to match the numbers of last year. And we haven't taken that in our targets also, honestly."

Dermicool Acquisition & Integration

Mohan Goenka: "So practically the sales become almost negligible. And prickly heat quickly there is no season, honestly."

Margins & Cost Pressures


Channel & Distribution Momentum


Rural & Healthcare Distribution Build-Out

Vinod Rao: "So the net of portfolio without balms, without pain portfolio, our rural is actually growing at 21%. So, it's doing well for us."

International Business

Vivek Dhir: "So despite the macroeconomic issues in Russia and Ukraine, we have been able to register a growth in quarter one."

Guidance & Commitments

CommitmentSpecificsTimeline
Gross margin recoveryPressure eases as high-cost RM inventory clears; full-year decline capped at 2%H2 FY23
Dermicool earnings contributionTrue benefit realized when summer loading startsJFM and April-June quarter
International growthDecent double-digit growth in every quarter (not 45%)Every quarter ahead
Rural footprint expansionReach close to 50,000 towns and villagesBy FY23 year-end
Healthcare OTC distributionAdd ~20% outlets and increase rural footprint by 20%; results expected in H2H2 FY23
A&P spendMaintained in the range of 17-18% of salesFull year FY23
Blended price increase4% to 4.5% for the full yearFull year FY23
Navratna recoveryReturn to prior peak levels if current growth trend sustainsOne to two years

Key Metrics

MetricQ1 FY23
Revenue₹778 cr, +18% YoY on a high base of 37% growth in Q4 FY22
Domestic sales growth+13% YoY on a high base of 42%, volume growth of 8%
International business growth+45% YoY on a base of 17%
Overall volume growth~10%
Gross margin62.6%, contracted 340 bps YoY due to inflation and adverse portfolio mix
EBITDA₹173 cr, +2% YoY
Adjusted PAT₹138 cr, flat YoY
Blended price increase4–4.5% taken across portfolio; full-year expected in same range
A&P spend guidance17–18% of sales planned for FY23
Gross margin guidance (FY23)Decline not expected to exceed 2% for the full year
Effective tax rate guidance~18% for remaining quarters, including MAT credit
Dermicool amortization (going forward)~₹22 cr per quarter for Dermicool and other brands
Navratna range growth+29% YoY
Kesh King range growth+20% YoY
Male Grooming growth+32% YoY
7 Oils in One growth+45% YoY
BoroPlus range growthFlat YoY; +6% on a three-year CAGR basis
Pain management category−30% YoY; +10% on a three-year CAGR basis
Healthcare range−25% YoY, led by immunity portfolio; +13% on a three-year CAGR basis
Domestic portfolio ex-pain, healthcare, Dermicool+30% value growth, +24% volume growth
Dermicool contribution to domestic sales~8%
Dermicool Q1 sales~₹63 cr (per an analyst's math)
Modern trade growth+42% YoY; contribution at 8.2% of domestic sales
E-commerce growth+55% YoY; contribution at 7.6% of domestic sales
CSD growth+23% YoY
Rural coverage41,000 towns and villages, up from ~32,000; target ~50,000 by year-end
Project Khoj rural manpower~1,300 people on ground, up from ~900
Rural growth ex-pain portfolio+21%
Kesh King shampoo share~25% of Kesh King portfolio
Bridge packs contribution2–3% of sales; reached 60–70% of core brand distribution